



Corporate Presentation

August 2026

Disclaimers

This presentation has been prepared by Evommune, Inc. (“we”, “us” or “our”) and contains forward-looking statements, including: statements about our expectations regarding the potential benefits, clinical activity and tolerability of our product candidates; our expectations with regard to the results of our clinical trials, preclinical studies and research and development programs, including the the potential therapeutic benefit of EVO756 and EVO301, the design, objectives, initiation, timing, progress and results of current and future preclinical studies and clinical trials of our product candidates, including the ongoing Phase 2 clinical trials for EVO756 and EVO301; anticipated cash runway; and continued advancement of our portfolio. These statements involve substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make.

These and other risks are described more fully in our Annual Report on Form 10-K for the year ended December 31, 2025 and our other filings with the Securities and Exchange Commission (the “SEC”) and our other documents subsequently filed with or furnished to the SEC. All forward-looking statements represent our views as of the date of this presentation. All forward-looking statements contained in this presentation speak only as of the date on which they were made. Except to the extent required by law, we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

This presentation also contains estimates made by independent parties relating to industry market size and other data. These estimates involve a number of assumptions and limitations, and you are cautioned not to give undue weight on such estimates. We have not independently verified the accuracy or completeness of such information and we do not take any responsibility with the accuracy or completeness of such information.

The trademarks included in this presentation are the property of the owners thereof and are used for reference purposes only.

Evommune (EVMN) is Addressing Chronic Inflammation, a Global Healthcare Crisis

3 of 5

Deaths Worldwide¹

**Chronic Inflammation
Destroys Lives**

\$90B

Annual Direct Cost²

**Substantial Burden on the
Healthcare System**

>50%

I&I Therapies Fail Patients

**Existing Treatment Options
Have Critical Limitations**

Evommune is Delivering Next Generation Therapies



Experienced Team



Distinct Mechanisms



Portfolio Approach

Our Mission-Driven Approach to Treating Immune-Mediated Diseases



Address critical gaps in care...




...Strategically select novel mechanisms with strong probability of success...




... Steady cadence of new programs entering the clinic

Two Phase 2 Programs with Novel Approaches to Targeting Heterogeneous Diseases

EVO756: Oral Therapy Targeting Mast Cells and Sensory Neurons



EVO301: IL-18 Blockade for Multi-Pathway Immunomodulation



Expansive Portfolio of Preclinical Programs

Strong Cash Position with Potential to Unlock Significant Near-Term Value Creation across Multiple Milestones

- ✓ **Mid-stage clinical company** developing novel therapeutics for highly prevalent chronic inflammatory diseases
- ✓ **Two clinically-validated programs in Phase 2:**
 - EVO756 (oral MRGPRX2 antagonist) in atopic dermatitis and migraine
 - EVO301 (long-acting IL-18bp fusion protein) in atopic dermatitis
- ✓ **Multiple clinical data readouts through 2028:**
 - EVO756 Phase 2b top-line data in AD expected in September 2026, planned Phase 3 in 1H 2027
 - EVO756 Phase 2b trial initiated in migraine in July 2026, top-line data expected in 2027
 - EVO301 reported positive data in a Phase 2a in AD (Feb 2026), moving to Phase 2b in 2027 with subcutaneous formulation, data expected in 2028
- ✓ **Steady cadence of new programs entering the clinic in a broad range of inflammatory diseases, with next preclinical program entering the clinic in 2027**
- ✓ **Proven and experienced leadership team has delivered almost 30 NDAs and BLAs**
- ✓ **~\$287 million of cash & investments as of June 30, 2026, with anticipated runway through 2028**


Proven and Experienced Leadership Team Has Delivered Almost 30 NDAs and BLAs



Luis Peña
Founder, President & CEO



Eugene Bauer, MD
Founder, CMO



Kyle Carver, MBA
CFO



Jeegar Patel, PhD
CSO



Greg Moss, Esq
CBO & CLO



Janice Drew, MPH
Chief of Development Operations



Daniel Burge, MD
SVP, Clinical Development



Lou Sehl, PhD
SVP, Technical Operations



Mark Jackson, MD
SVP, Clinical Development

Leadership in >25 Companies

Dermira
(Acquired by Eli Lilly for \$1.1B)

Lilly

Genentech
A Member of the Roche Group

STIEFEL

(Acquired by GlaxoSmithKline for \$2.9B)

Peplin
Innovation in Dermatology

(Acquired by LEO Pharma for \$288M)

PROTEOLIX

connetics
(Acquired by Stiefel for \$930M)

GSK

Kadmon
(Acquired by Sanofi for \$1.9B)

sanofi

Stanford MEDICINE

Allergan

MYOKARDIA
(Acquired by Bristol Myers Squibb for \$13.1B)



ImClone Systems
(Acquired by Eli Lilly for \$6.5B)

COHESION
(Acquired by Angiotech for ~\$50M)

Roche

Key Roles in Almost 30 NDA / BLAs

Ebglyss
(tebrikizumab-lbkl)
250mg/2mL injection

REZUROCK
(belumosudil) tablets

Xolair
Omalizumab
FOR SUBCUTANEOUS USE 75 mg + 150 mg

cimzia
(certolizumab pegol)

BOTOX
OAB

eucrisa
crisaborole ointment 2%

TNKase
Tenecteplase For Fast Lytic Delivery in AMI

ACTIVASE
ALTEPLASE
A RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR

Qbrexza
(glycopyrronium) cloth

Kyprollis
(carfilzomib) powder for injection

Lartuvo
(OLARATUMAB) Injection 10 mg/mL

Portrazza
necitumumab injection 800 mg/50 mL vial

Picato
(ingenol mebutate) gel 0.015%, 0.03%

SORIATANE
(acetrelin) Capsules

CYRAMZA
(ramucirumab)s

extina
(ketconazole) Foam, 2%

CAMZYOS
(mavacamten) capsules

CLOVIQUE
Trentine Hydrochloride Capsules, USP

Coseal
Surgical Sealant

CellCept
(mycophenolate mofetil)

Liletta
(levonorgestrel-releasing intrauterine system) 52mg

Kerydin
(TAVABOROLE) TOPICAL SOLUTION, 5%

veltin
(clindamycin phosphate and tretinoin) Gel 1.2%/0.025%

Vitagel

evoclin
(clindamycin phosphate) Foam, 1%

FABIOR
(tazarotene) Foam, 0.1%

Our Inflammation Portfolio


Program / Target	Indication	Preclinical	Phase 1	Phase 2	Phase 3	Next Anticipated Milestone
EVO756 MRGPRX2	Atopic Dermatitis					Phase 2b data (September 2026)
	Migraine					Phase 2b trial initiated; Top-line data (2027)
	Other Indications					Phase 2 trial planning underway
EVO301 IL-18BP	Atopic Dermatitis					- Positive Phase 2a POC: Full data to be presented at an upcoming medical meeting - Phase 2b trial planning underway
	Ulcerative Colitis					Phase 2 trial planning underway
	Other Indications					Phase 2 trial planning underway

Advancing Multiple Preclinical Programs Toward Clinical Proof-of-Concept

EVO756: Oral MRGPRX2 Antagonist

First and Best-in-Class Dual Mechanism Modulates Both Peripheral Sensory Neurons and Mast Cells

MRGPRX2 in Neuroinflammation and Mast Cell Activation



Tissue Pathophysiology

Neuronal Sensitivity

Inflammatory Infiltrates

Increased Mast Cell Numbers

Innate Immunity

Adaptive Immunity

Tissue Remodeling

Vascular Leak

Clinical Manifestations

Itch / Pain / Cough

Chronic Inflammation

Erythema

Hives

Barrier Dysfunction

Airflow Limitation

Edema Angioedema


Sensitivity to Chemicals / Foods

EVO756: Broad Spectrum Oral Anti-Inflammatory Potential


Potential First-Line Oral Across Several Specialties

- Potent and highly selective small molecule
- Oral convenience could drive adoption across multiple indications
- Anticipate favorable safety and tolerability profile

MRGPRX2 Expressed on Both Sensory Neurons and Mast Cells



Sensory Neurons and Mast Cells Are Found in Close Proximity



EVO756: Differentiated Mechanism Across Multi-Billion-Dollar Markets


Sequenced Expansion Across Underserved, Blockbuster Markets

Initial Target Population

Selected for unmet need, market size, and defined regulatory path

~45M

Eligible Patients





Today

Future Target Population

>95M Patients

Expanding into High-Potential Indications
Where Neuroinflammation Drives Disease



EVO756 Clinical Development Overview


Trial	Phase 1 Proof-of-Concept	Phase 2	Phase 2b	Phase 2b
N	132	30	~120	~330
Indication	Healthy Volunteers	CIndU	AD	Migraine
Key Takeaways	- Well-tolerated across all doses - Clear target engagement in skin challenge ~70% human skin penetration - PK supports full target coverage as low as 25mg BID	- Well-tolerated across all doses - Complete responses as early as week 1 - Clear POC achieved with 70% FricTest responders - Similar activity at 50mg BID and 300mg QD doses	Top-line Data Expected September 2026	Trial Initiated in July 2026, Top-line Data Expected 2027

EVO756: Phase 1 Proof-of-Concept Trial Design and Summary

Inclusion of Icatibant Skin Challenge Demonstrated EVO756 Target Engagement in Humans


PART A: SAD Dosing

N = 55 (41 active / 14 placebo)



PART B: MAD Dosing

N = 77 (58 active / 19 placebo)



*Included Skin Challenge
at All Doses*

Pharmacokinetics

- Concentration dose proportional and linear
- Half-life ranges from 8 - 12 hours
- T_{max} : 1 - 4 hours
- Support QD and BID dosing

Pharmacodynamics – Icatibant Skin Challenge Test


- Clear target engagement
- Dose dependent activity
- All doses associated with response

Safety

- Well-tolerated across all doses
- No severe or serious adverse events
- No clinically significant abnormal lab values
- No clinically significant ECG abnormalities

EVO756 PK Supports Full Target Coverage as Low as 25mg BID

Day 10 Median Concentrations



Dose-Proportional

- Linear concentration-dose relationship across SAD and MAD cohorts

Half-Life: 8-12 Hours

- T_{max} 1–4 hours · supported both QD and BID dosing

High Skin Penetration

- ~70% tissue:plasma ratio in human skin 2-fold accumulation
- 17% free drug ratio

Positive Phase 2 CIndU Data Validated EVO756 Activity

Robust Efficacy at Week 4 Competitive with Omalizumab and Barzolvolimab

30%

Complete Response

at Week 4 across both doses
(8 of 27 patients · FricTest score = 0)


70%

FricTest Response

≥1-point improvement at Week 4
(19 of 27 patients)

- Symptomatic dermatographism (N=30)
- Open-label, within-patient controlled
- 50 mg BID and 300 mg QD over 4 weeks
- FricTest: standardized friction provocation test (0–4)

Clinical Improvements Over Time



For illustrative purposes only. Not a head-to-head comparison. Differences exist between trial designs and study characteristics, and caution should be exercised when comparing across trials. Sources: Evommune clinical data (observed), competitor data from Maurer *et al.* (2017), Maurer *et al.*, ACAAI (2024)

Safety Summary

Well Tolerated Across All Evaluated Dosing Levels

Summary of Treatment Emergent Adverse Events Occurring in >1 Patient

	300 mg QD N = 11	50 mg BID N = 19
ALT/AST Increased	2 (18%) ¹	–
Gastroenteritis	1 (9%)	1 (5%)
Pruritus	1 (9%)	1 (5%)

EVO756 was Generally Well Tolerated

-  No serious adverse events
-  No treatment discontinuations due to adverse events


Evommune clinical data; ALT = alanine aminotransferase; AST = aspartate aminotransferase; 1. The two subjects in the 300 mg QD cohort with AEs of increased ALT and AST had asymptomatic transaminase elevations that were greater than ten times the upper limit of normal at four weeks, which were not present at baseline, week 1 or week 2 and later returned to baseline. Other liver tests, including bilirubin and alkaline phosphatase were within normal limits. Both of these subjects had confounding factors that may have contributed to these elevations.

EVO756 Phase 2b Dose Selection Rationale

Understanding of Dose Response Evolved During CIndU Study, Guiding Phase 2b Trial Doses

HV Icatibant Skin Challenge

- Active across all icatibant doses
- **10 µg/mL icatibant dose is most relevant comparison** based on patient biopsies
- Suggests **potential activity as low as 10 mg BID**



PK/PD Modeling

- Refined model to predict IC₉₀ coverage at trough
- Suggested **complete coverage as low as 25 mg BID**
- **High tissue penetration** in human skin (~70%)

EVO756 Phase 2 CIndU Results

- Strong activity in 300 mg QD dose **provided confidence to explore lower doses**
- 50 mg BID dose had similar activity


Selection of Phase 2b Doses

Potential for large therapeutic window; driving approach to dose-ranging trials

EVO756 in Atopic Dermatitis (AD)

MRGPRX2 is Only Dual MOA: Targeting Inflammatory Lesions and Neuroinflammation

Expect Benefit on Neuroinflammation and Mast Cell Aspects of AD



Strong Scientific Rationale for EVO756 in AD



Neuroinflammatory and mast cell disease

Dual mechanism impacting key inflammatory pathways



Rapid impact on itch

Direct effect on sensory neurons



Broad therapeutic potential

MOA likely effective across patient endotypes



Strong translational validation

Pathway activation in disease and preclinical evidence of Mrgprb2/X2 involvement

AD Still Has No First-Line Oral Option

No Current Oral Therapy Combines Lesion Control, Itch Relief, and Tolerability

~15M

Targeted-Therapy
Eligible Patients

EVO756 – Promising First-Line Candidate Designed to Deliver on All Three:

1

Oral Dosing

Preferred ROA

2

Differentiated Activity

MOA Targets Lesions + Itch

3

Well-Tolerated

Profile Supports Broad Use

CytoReason Collaboration: *in silico* AD Model Identifies and Validates Opportunities Beyond IL-4/IL-13

MRGPRX2 Signature Generation




From RNAseq of *in vitro* human mast cells activated with MRGPRX2 ligands with/without EVO756

Computational Engine




Integration of MRGPRX2 signature, 24 RNAseq datasets, >2,000 of human skin biopsies

Clinical Anchoring




Model calibration against EASI scores and Dupilumab response data

in silico AD Model



Acts as digital twin by integrating high-dimensional molecular data with real world clinical endpoints

Predictive Modeling Reveals MRGPRX2 as a Core to AD Pathophysiology



Broad reach may enable EVO756 to potentially outperform IL-4/-13–restricted approaches

MRGPRX2 Captures Core IL-4/-13 Biology and Broader Disease Drivers

Shared Biology


- MRGPRX2 and IL-4/-13 signatures capture both Th2 inflammation and neuroinflammation

Differentiated Coverage

- MRGPRX2 uniquely captures “white space” biology, including cellular proliferation and barrier pathways
- MRGPRX2 molecular signature remains expressed in non-responders to IL-4/-13 standard of care

Implications

- Complementary—not redundant—mechanism
- Potential to expand efficacy beyond current standard of care




Phase 2b Dose-Ranging Trial in AD

Top-Line Data Expected September 2026

Adults with Moderate-to-Severe Atopic Dermatitis (N = 120)

Randomized, Double-Blind, Placebo-Controlled Trial



Primary Endpoint

- % change in EASI from BL at Week 12

Key Secondary Endpoints

- EASI-50, EASI-75, and EASI-90
- Change in vIGA
- Change in Pruritus-NRS
- Proportion of patients achieving ≥ 4 point reduction in Pruritus-NRS
- Change in BSA affected

Exploratory Biomarkers

- Patient subtyping
- Pharmacodynamics & disease severity

EVO756 in Migraine

MRGPRX2 is a Novel Migraine Target with Potential to Address Neuroinflammatory and Mast Cell Drivers of Migraine

Strong Scientific Rationale for EVO756 in Migraine



Disease-Relevant Expression

MRGPRX2 is expressed in human trigeminal neurons and meningeal mast cells



Preclinical Validation

in vivo headache models support pathogenic role for MRGPRX2



Translational Insights

Multiple MRGPRX2 ligands induce migraine in humans



Clinical Proof-of-Concept

mAb inhibition of MRGPRX2 ligand (PACAP) shows clinical benefit

EVO756: Targeting Major Unmet Need in Migraine Prevention

~30M

G7 Patients Eligible for
Preventative Therapy

EVO756 – Defining the Next Wave of Preventatives

1

Oral Dosing

Preferred ROA

2

Novel Dual Mechanism

Targets neurons + mast cells;
Blocks 3 migraine triggers
(PACAP, VIP, Substance P)


3

First-Line Potential

AHS now recommends targeted
therapies first-line


High Demand for Preventative Migraine Therapy

Prevention Drives ~50% of \$25B Migraine Market



>75M People Living with Migraine Worldwide

Most Patients Remain on Legacy Preventives — Targeted Therapies Drive Sales



~30M Global Patients Eligible for Preventative Therapy


Sources: Clarivate "Migraine: Disease Landscape and Forecast" (2026), AHS guidelines for migraine prevention eligibility, Buse *et al.* (2024), Silberstein *et al.* (2015), Cohen *et al.* (2024), Coppola *et al.* (2025), Sakai *et al.* (2022). Note: Sales represent 7 Major Markets (US, EU5, Japan); Percent of patients by therapy type exceeds 100% due to co-prescribing; % patient numbers by therapy reflect US patient breakdown.

Innovation in Migraine Prevention Has Been Limited to CGRPs

Preventive Innovation has Clustered Around a Single Target (CGRP)

Advanced Treatments	Class	Route of Administration
 QULIPTA [®] (atogepant) tablets	CGRP	Oral QD
 Nurtec [®] ODT		Oral EOD
 Vyapti		IV
 Emgality [®]		SC
 aimovig [®] erenumab		SC
 AJOVY	Neurotoxin	SC
 BOTOX [®] onabotulinumtoxinA ^{injection}		IM

Migraine Burden Persists Despite Oral CGRP Therapy



- Many chronic patients still experience >12 monthly migraine days on treatment

High Unmet Need in Migraine Prevention

Limited Therapeutic Diversity

- Only CGRP inhibitors and neurotoxin

Inadequate Efficacy


- ~45% of patients do not achieve 50% improvement

Tolerability Challenges Remain

- CGRPs associated with constipation, hypertension, Raynaud's, nausea, allergic and injection site reactions


MRGPRX2: Positioned to Address Neuronal and Mast Cell Drivers of Migraine

MRGPRX2 Mediates Neuropeptide Signaling Associated with Migraine (PACAP, VIP, Substance P)




Expression Confirmed in Disease-Relevant Tissues

Trigeminal Ganglia



Meningeal Mast Cells




PACAP Triggers Migraine via MRGPRX2¹ as Primary Receptor *in vivo*

MRGPRX2 Ligand PACAP Induces Headache *in vivo*

- 1 PACAP injected directly to meninges of wild type and knockout models
- 2 Facial withdrawal threshold used as functional pain readout

Knockout of MRGPRX2¹ Reduced PACAP-Induced Migraine Symptoms




- *in vivo* data support functional role of MRGPRX2¹ signaling in migraine

MRGPRX2 Ligands Induce Migraine in Humans


PACAP, VIP, Substance P are Known MRGPRX2 Agonists

PACAP, VIP, Substance P Infusion all Induce Migraine-Like Headache in Migraineurs



- Similar to CGRP, which induces migraine in ~2/3 patients


PACAP-Induced Headaches More Closely Recapitulate Migraine Features vs. CGRP



Note: Data shown from PACAP-38; PACAP-27 also induces migraine. Sources: Adapted from PMID19052139, PMID34357396, PMID37009867, Al-Khazali *et al.*, (2026). Note that there have been multiple studies inducing headache/migraine with ligands and experimental paradigms / results differed. Data shown represent cumulative observations pooled across multiple trials and cannot support definitive conclusions.

PACAP Likely Induces Migraine in Humans Through MRGPRX2 as Primary Receptor

PACAP Impact in Migraine Is Primarily through MRGPRX2




PACAP Receptor	Relevant Tissue Expression	Preclinical Evidence?	Clinical Validation In Migraine?
PAC1	Neurons ¹	Limited	
VPAC1 VPAC2	Cranial vessels Neurons (?)	Limited	<i>Not evaluated</i>
MRGPRX2	Mast Cells Sensory Neurons		TBD

1. Trigeminal sensory neurons, brainstem pain circuits, hypothalamus, cortex, thalamus. Note: In addition to MRGPRX2 PACAP binds PAC1, VPAC1, VPAC2, but PAC1 inhibition (Amgen’s AMG301: PAC1 blocking mAb.) does not show therapeutic benefit in migraine. Sources: PMID: 33231489, PMID: 39085771, PMID: 37706270.

Inhibition of MRGPRX2 Ligand PACAP Achieves CGRP-Like Efficacy in Migraine Prophylaxis

Lundbeck's Bocunebart Reduced Monthly Migraine Days by ~2



- Magnitude of benefit consistent with marketed CGRP inhibitors


Second Neuropeptide Axis Validated in Migraine Prevention

- ✓ PACAP likely acts through MRGPRX2 as a key neuropeptide trigger of migraine attacks
- ✓ Antibody blockade reduced migraine frequency in controlled clinical study
- ✓ Effect size falls within range observed for approved CGRP therapies

Note: Lundbeck's bocunebart is a humanized mAb that neutralizes PACAP. Results above from Phase 2 a study in migraine prophylaxis (HOPE; N=237; single IV administration of bocunebart in patients that were a mix of episodic and chronic migraineurs). Source: Clinicaltrials.gov NCT05133323. Direct comparisons cannot be made in the absence of head-to-head trials because of differences in trial design, patient population and other factors.

MRGPRX2 Inhibition May Offer Broader Migraine Benefit than Targeting PACAP Alone


3 Neuropeptides that Trigger Migraine Signal Through MRGPRX2




Neuropeptide	Preclinical Evidence	Induced Headache in Humans	Clinical Validation
PACAP	✓	✓	✓
VIP	✓	✓	TBD
Substance P	✓	✓	TBD

EVO756 Potently (low nM) Inhibits PACAP, Substance P and VIP-Induced MRGPRX2 Activation *in vitro*

EVO756 Inhibits Migraine Relevant Endogenous Ligands in X2-CHO Cells



EVO756 Inhibits PACAP and SP-Induced Primary Human Mast Cell Activation *in vitro*




Phase 2b Dose-Ranging Trial in Migraine Prophylaxis

Top-line Data Expected in 2027

Adults with Refractory Migraine ≥ 6 Days/Month (N $\approx$ 330)

Randomized, Double-Blind, Placebo-Controlled Trial



Exploring daily doses up to 100 mg

Primary Endpoint

- Mean CFB in MMD

Key Secondary Endpoints

- $\geq 50\%$, $\geq 75\%$ reduction in MMD
- CFB in MHDs and MMD
- CFB in monthly acute migraine medication use


Exploratory Endpoints

- Patient subtyping
- Changes in biomarkers
- Change in migraine-specific QoL

EVO301: Best-in-Class IL-18BP Fusion Protein

Long-Acting Serum Albumin-Binding Injectable Therapeutic Fusion Protein Designed to Neutralize IL-18 Signaling


EVO301 Could Command Substantial Market Share in the Potentially \$60B+ AD Market as a Clearly Differentiated Biologic

Sales in \$M	Class	Route of Administration ¹	Launch Year	2025 WW Sales	2025 US Sales	Projected Growth ²	Projected Peak WW AD Sales in \$M
 DUPIXENT (dupilumab)	IL-4/-13	Q2W SubQ	2017	\$12,496	\$9,234	+9%	\$17,423 (2030)
 Adbry (tralokinumab-ldrm) Injection 150 mg • 300 mg	IL-13	Q2W SubQ	2021	\$1,508	\$1,421	+22%	\$2,469 (2030)
 Ebglyss (lebrikizumab-lbkz)	IL-13	Q4W or Q8W SubQ	2024	\$533	\$274	+72%	\$2,625 (2032)
 nemluvio (nemolizumab-ilto) for injection 30 mg	IL-31	Q8W SubQ	2024	\$339	\$172	+91%	\$2,759 (2032)

Four Marketed AD Biologics Currently ~\$15B, Projected to be ~\$25B by 2032


Proven Playbook, Larger Market: AD Projected to Reach ~\$60B

10 of 14 Psoriasis Advanced Therapies Became Blockbusters — And AD Has ~5x the Patients



Per Evaluate Pharma (May represent projections and not actual sales); "Year 1" for AD represents 2017 (year of Dupixent launch); "Year 1" for Psoriasis represents 2004 (year of Enbrel launch in plaque psoriasis); 1. Total estimated prevalence in adult and pediatric populations from Decision Resources DL&F; 2. Total estimated prevalence in adult and pediatric populations; Estimated per psoriasis.org, datacenter.aecf.org, Armstrong et al. (2021), Paller et al. (2018), Tannenbaum et al. (2022), Helmick et al. (2014), Rosario-Jansen et al. (2025). Note this slide contains registered trademarks not owned by Evommune. AD market size from Evaluate and internal analyses.

EBGLYSS and NEMLUVIO Launches in AD Outpacing Historical Psoriasis Launches, Highlighting Need for New Options in AD



Both EBGLYSS and NEMLUVIO, Launched in 2024, Projected for \$2.5B+ Global Sales


EVO301 Addresses Limitations of Existing Biologics; Demonstrating Ability to Impact Multiple Drivers of AD, While Being Well Tolerated

Biologic Pathway	Adaptive Inflammation			Innate Inflammation	Skin Barrier (IL-22)
	TH2	TH1	TH17		
IL-18	✓	✓	✓	✓	✓
DUPIXENT®	✓	✗		✓	✓
EBGLYSS®	✓	✗		✓	✓
ADBRY®	✓	✗		✓	✓
NEMLUVIO®	✓				✓


Broader inflammatory signaling of IL-18 can address endotypes not fully captured by Th2-targeted therapies — enabling potential for broader patient coverage and efficacy

IL-18 Immune Rebalancing: Modulate Innate and Adaptive Inflammation for Potential Disease Remission


Involved in Innate and Adaptive Immune Processes



IL-18BP Therapeutic Approach



IL-18 Plays Key Role Across Multiple Chronic Inflammatory Diseases



EVO301: Long-Acting IL-18BP Neutralizer Designed for Tissue Targeting


SAFA and IL-18BP Fused Via Peptide Linker for Extended Neutralization of IL-18 Activity

SAFAbody™ Platform Technology

- $T_{1/2}$ extension: FcRn-mediated recycling of HSA
- Efficient tissue distribution:
 - Smaller size (MW ~65 kD) and HSA binding

IL-18 Binding Protein (IL-18BP)


- High binding affinity and specificity
- Native fully human sequence



EVO301 Phase 2a Proof of Concept Trial Design

Adults with Moderate-to-Severe Atopic Dermatitis (N = 70)

Randomized, Double-Blind, Parallel Group, Placebo-Controlled Trial



AD Population

- EASI ≥ 16
- vIGA ≥ 3
- BSA $\geq 10\%$

Primary Endpoint

- Percent change from EASI at Week 12 (Bayesian)

Pharmacokinetics

Target Engagement

EVO301 Achieved the Primary Endpoint

Phase 2a Proof-of-Concept Trial in Moderate-to-Severe Atopic Dermatitis

- **Highly statistically significant EASI reductions at weeks 4, 8, and 12 versus placebo**
- **34% and 33% placebo adjusted improvement in EASI at week 8 and 12, respectively**
- **23% of patients achieved IGA 0/1 at week 12 versus 0% placebo**
- **Well-tolerated, with no treatment related serious or severe adverse events reported**
- **Corresponding reductions in secondary endpoints, as well as key Th2 and non Th2 cytokines**
- **Pharmacokinetics (PK) continues to support a Q4 week dosing regimen**


Phase 2a Profile Supports Potential Best-in-Class Monotherapy in Atopic Dermatitis

Phase 2a Trial in AD Met Primary Outcome Measure (Bayesian)


% Change in EASI at Week 12: Protocol Success Criterion Met

Statistic	EVO301 versus Placebo
Success Criterion: Posterior Probability of Difference < -8%	75%
Trial Results: Posterior Probability of Difference < -8%	99.8%
Posterior Mean Difference	-32
95% HPD Interval for Difference in Mean	-47, -15


Phase 2a Trial in AD Demonstrated Statistically Significant Efficacy Across Time Points



Two Doses of EVO301 Demonstrated Comparable Activity at 12 Weeks to Dose-Optimized Marketed Biologics at 16 Weeks



Phase 2a Trial in AD: Early Clinical Signal in vIGA 0/1 Response



Visit	EVO301	Placebo
Week 4	4.2%	0%
Week 8	12.5%	0%
Week 12	22.9%	0%

Safety Summary Over 12 Week Trial Period

EVO301 Was Well Tolerated


	EVO301	Placebo	Total
	N=48	N=22	N=70
Patients with ≥ 1 Adverse Event (AE)	30 (62.5%)	16 (72.7%)	46 (65.7%)
Patients with ≥ 1 Treatment Related AE	5 (10.4%)	3 (13.6%)	8 (11.4%)
Patients with a Related Serious or Severe AE	0	0	0
AEs Leading to Study Discontinuation	0	0	0

AEs > 5% in Either Arm	EVO301	Placebo	Total
Upper respiratory tract infection	10 (20.8%)	4 (18.2%)	14 (20.0%)
Atopic dermatitis	10 (20.8%)	9 (40.9%)	19 (27.1%)
Headache	8 (16.7%)	3 (13.6%)	11 (15.7%)
Nasopharyngitis	4 (8.3%)	0	4 (5.7%)
Viral upper respiratory tract infection	3 (6.3%)	2 (9.1%)	5 (7.1%)
Dizziness	3 (6.3%)	1 (4.5%)	4 (5.7%)
Fatigue	3 (6.3%)	0	3 (4.3%)

**No Clinically Significant Lab Abnormalities.
No Conjunctivitis Reported (as is Common with Other Biologics in AD)**

EVO301 Subcutaneous Formulation Exposure Consistent with IV

Comparable Nonclinical Serum Exposure



Key PK Parameters


Parameters	10 mg/kg (N = 3/group)	
	Intravenous (IV)	Subcutaneous (SC)
C _{max} (µg/mL)	343	90
AUC (µg•hr/mL)	~27,000	~27,000
T _{max} (hr)	0.83	72
T _{1/2} (hr)	101	168

Planned EVO301 Phase 2b Dose-Ranging Trial in AD

Trial Initiation Expected Mid-2027

Adults with Moderate-to-Severe Atopic Dermatitis (N ≈ 180)

Randomized, Double-Blind, Placebo-Controlled Trial



Primary Endpoint

- % CFB in EASI at Week 16

Key Secondary Endpoints

- EASI-50, EASI-75, and EASI-90
- Change in vIGA
- Change in Pruritus-NRS
- Proportion of patients achieving ≥ 4 point reduction in Pruritus-NRS
- Change in BSA affected

Exploratory & Biomarkers

- QoL
- Biomarkers
- Target Engagement

Thank You!